Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Surgical Procedures, Operative 7Liver Transplantation 5Lenalidomide 4Blood Specimen Collection 4pomalidomide 3Neoadjuvant Therapy 3Liquid Biopsy 3gilteritinib 2Therapeutics 2Rituximab 2Proteasome Inhibitors 2Observation 2Mohs Surgery 2Mitomycin 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Immunoconjugates 2High-Throughput Nucleotide Sequencing 2Fluorouracil 2Drug Therapy 2DNA, Mitochondrial 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2Antibodies, Monoclonal 2Antibodies, Bispecific 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1romidepsin 1nedaplatin 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Recurrence × romidepsin × Clear all
NCT03742921 2023-12-06

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Celgene

Completed
150 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡